anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Ultrasound performed after extubation has been suggested to be useful for the diagnosis of recurrent laryngeal nerve (RLN) paralysis. However, the use of ultrasound for this purpose before extubation has not been examined. The aim of this study was to examine the versatility (interrater reliability) and usefulness of ultrasound for evaluating the movement of vocal cords before extubation.
METHODS: The subjects were 30 patients who underwent radical surgery for esophageal cancer from August 2020 to December 2021. An experienced examiner performed an ultrasound examination before and after elective extubation on the day after surgery to evaluate RLN paralysis and record videos. Bronchoscopy was then performed to make a definite diagnosis. Three anesthetists blinded to the diagnosis also evaluated the cases using the videos, and the versatility of the examination was determined using a kappa test.
RESULTS: The diagnostic accuracies of the examiner and three anesthetists were 76.7%, 50.0%, 53.3%, and 46.7%, respectively, and the kappa coefficients for the examiner with the anesthetists were 0.310, 0.502, and 0.169, respectively. The sensitivity, specificity, positive predictive value and negative predictive value for diagnosis of RLN paralysis by the examiner using ultrasound before extubation were 0.57, 0.95, 0.80, and 0.87, respectively.
CONCLUSION: These results indicate a lack of versatility of the ultrasound examination based on the low kappa coefficients. However, with an experienced examiner, ultrasound can serve as a non-invasive examination that can be performed before extubation with high accuracy and specificity for diagnosis of postoperative RLN paralysis.
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit kinase. In the phase Ⅲ study, patients who failed at least two kinds of systemic chemotherapy (third line or beyond) or drug intolerance were treated with anlotinib（12mg，po. qd. on day 1to14 of a 21-day cycle） or placebo, the anlotinib group PFS and OS were 5.37 months and 9.63 months, the placebo group PFS and OS were 1.4 months and 6.3 months. Therefore, the investigators envisage using anlotinib plus docetaxel treat the advanced Non-small cell lung cancer patients who were failure of first-line Chemotherapy , to further improve the patient's PFS.
Management of pancreatic disorders imparts a major burden on healthcare costs, estimated at over 3 billion dollars annually. Chronic pancreatitis is characterized by chronic inflammation and progressive scarring, leading to abdominal pain, irreversible damage to the pancreas and the loss of both exocrine and endocrine function. Additionally, chronic pancreatic inflammation is a risk factor for pancreas cancer. There are no current treatments to modify the natural history of this disorder. Thus, identifying novel therapeutic options for this disease represents a high priority, and could fill an unmet medical need to improve quality of life, reduce risk of malignant transformation, and limit exorbitant medical costs associated with patient care. The investigators have assembled a multi-disciplinary research team to pursue an alternative, non-pharmacologic approach to limiting inflammatory cascades in (Chronic Pancreatitis) CP patients. They will assess compliance, toxicity and measure the changes in pro-inflammatory cytokine expression from a soy based dietary bread product using a classic 3+3 dose escalation study design in subjects with chronic pancreatitis.
The study was carried out on 34 male volunteer patients aged 35-75 years, newly diagnosed with coronary artery disease (CAD) by conventional coronary angiography. The study did not include the individuals who have dieted in the last six months, been taking an omega-3 FA and/or vitamin/mineral supplements or statin group drugs, been BMI \<18.5 and ≥40 kg/m2, been fasting blood glucose ≥ 126 mg/dL, had a systemic disease such as Type 1 and Type 2 diabetes, kidney diseases, liver diseases, cancer and neurological diseases, active athletes, regular exercisers. Gazi University Faculty of Medicine Clinical Research Ethics Committee approved the study on 26 November 2020 with approval number 810. In addition, the necessary approval was obtained from the Turkish Medicines and Medical Devices Agency with the decision numbered 66175679-514.11.01-E.290378. All participants gave signed informed consent and the study was conducted in accordance with Helsinki Declaration.

Patients with CAD were divided into the "Omega-3 Group (n:16)" and "Control Group (n:18)" to evaluate the effects of omega-3 FA supplementation on biochemical parameters, especially serum fetuin-A, anthropometric measurements, and nutritional status. 1.560 mg/day omega-3 FA supplementation was applied for 8 weeks to 16 participants with CAD included in the omega-3 group, and the principles of a low-fat diet were explained. The principles of the low-fat diet without omega-3 FA supplementation were explained to 18 participants with CAD in the control group. The data of the participants were collected at the beginning, every 15 days and at the end of the 8th week.
FIELD: food industry. SUBSTANCE: invention elates to method for preparing water-dispersable oryzanol composition wherein sterol is in easily using form. Method involves spraying drying of oryzanol suspension in the presence of monofunctional and polyfunctional surface-active agents. Product is prepared in form that can be added to foodstuffs or beverages or to solid or suspension standard forms. EFFECT: improved preparing method. 12 cl, 6 ex
Phase II will consist of a randomized trial comparing intranasal ketorolac to Diclofenac, a commonly used oral NSAID. , Diclofenac potassium. Following ureteroscopy and stent placement, patients will receive standard of care medications to mitigate post operative pain and stent discomfort, and will be randomized to receive either as needed intra-nasal ketorolac or oral diclofenac. We seek to enroll and randomize 60 patients in a 1:1 fashion. Analysis will be intention to treat.
The study is designed as a placebo controlled trial that tests the effects of 6 month supplementation with 2 eggs or 4 ounces of egg substitute a day on cognitive function in older adults. Subjects will be randomly assigned to one of the two groups. Secondary analyses will determine whether baseline macular pigment density (a non invasive measure of lutein and zeaxanthin in neural tissue) or choline status predicts relative effectiveness of the intervention on cognitive function. Secondary outcomes include plasma biomarkers of oxidative stress and inflammation, choline bioavailability, and genetic variants related to endogenous choline production. Participants will be recruited from community-dwelling men and women aged \> 50 yr, and potential participants will be screened to meet cognitive and functional criteria. Participants will be pre-screened by telephone; those who appear to meet criteria will undergo further screening. The study will include baseline (0 month), 3 and 6 month visits for study procedures, and monthly telephone calls. Given that there is a visible difference between the two interventions (eggs, egg substitute), a blinded study is not possible.
Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to HE4. Monoclonal antibodies having the binding characteristics of an HE4 antibody of the invention are further provided. Hybridoma cell lines that produce an HE4 monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed HE4 monoclonal antibodies and for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an HE4 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention.
An injectable medication tab used to track expiration dates has an informative tab, a release string, an adhesive liner, and a quick release fastener. The informative tab provides visually accessible information about a bottle to which the injectable medication tab is attached. An expiration information portion of the informative tab protrudes from the exterior surface of the bottle after being opened. The adhesive liner is superimposed onto a mounting surface of the informative tab and attaches the informative tab to the bottle. The quick release fastener is a coupling mechanism that connects between an edge of the informative tab and the release string. The release string forms a detachable connection holding the expiration information portion against the bottle until the bottle is opened. Once opened, the expiration information section to protrudes from the bottle until the expiration information is recorded and the medical information portion is adhered to the bottle.
The control group will be asked not to change their physical activity for 8 weeks. After that period and post-test the control group will receive the exercise.
A method of monitoring and dispensing controlled substances includes providing a machine containing a plurality of controlled substances. Each of the controlled substances is in the machine in a separate vessel. The machine is connected with a network having an accessible patient information database. The machine receives, from the network, an order for a specific patient having a specific patient record in the patient information database for a prescribed amount of one of the controlled substances. The machine dispenses only the prescribed amount of the one controlled substance to a container from one of the separate vessels. The machine or the network permits an authorized user to retrieve the container having the dispensed prescribed amount of the one controlled substance from the machine to fill the order. The process is repeated when a new order is received by the machine from the network for any one of the controlled substances.
Exposure to sunlight (including sunlamps) should be avoided or minimized during use of ALDARA Cream because of concern for heightened sunburn susceptibility. Patients should be warned to use protective clothing (e.g., a hat) when using ALDARA Cream. Patients with sunburn should be advised not to use ALDARA Cream until fully recovered. Patients who may have considerable sun exposure, e.g., due to their occupation, and those patients with inherent sensitivity to sunlight should exercise caution when using ALDARA Cream.

ALDARA Cream shortened the time to skin tumor formation in an animal photococarcinogenicity study [see Nonclinical Toxicology (13.1)] . The enhancement of ultraviolet carcinogenicity is not necessarily dependent on phototoxic mechanisms. Therefore, patients should minimize or avoid natural or artificial sunlight exposure.
A cell destruction method includes providing an anionic biomarker that comprises a magnetic material such as an iron or an iron compound. The anionic biomarker is introduced into an organism having pathogen cells with a negative charge. The anionic biomarkers are attracted to the negative charges of the pathogen and couple thereto. The anionic biomarker may also have a coupler portion that further aids in the anionic biomarker coupling to and being bound to the pathogen cell and/or cell wall. An electric field may be produced to cause the anionic biomarkers and/or the negative charges of the pathogen cell to polarize on or along the pathogen cell. A magnetic field is directed to cause the anionic biomarker, or magnetic material thereof to move and damage the cell. The magnetic field may be an alternating magnetic field that causes the magnetic material to oscillate and damage the cell wall.
Chronic myeloid leukemia (CML) is characterized by leukocytosis with left-shifted neutrophilia, basophilia, eosinophilia, and variable thrombocytosis. However, extremely rare cases of patients with CML without significant leukocytosis and thrombocytosis (aleukemic phase [ALP] CML, or CML-ALP) have been reported. Due to its rarity and limited awareness, there remains a significant knowledge gap concerning the pathologic diagnosis, disease progression, and optimal patient management and outcomes. In this multi-institutional study, we investigated 31 patients with CML-ALP. Over half (54.8%) of patients had a history of or concurrent hematopoietic or nonhematopoietic malignancies. At time of diagnosis of CML-ALP, approximately 26.7% of patients exhibited neutrophilia, 56.7% had basophilia, and 13.3% showed eosinophilia. The median number of metaphases positive for t(9;22)(q34;q11.2) was 15, with a median of 38.5% of interphase nuclei positive for BCR::ABL1 by fluorescence in situ hybridization. The median BCR::ABL1 level was 26.14%. Remarkably, 14 (45.2%) patients were initially misdiagnosed or not diagnosed before karyotype or fluorescence in situ hybridization information for BCR::ABL1 became available. Twenty-five patients received tyrosine kinase inhibitors (TKIs). One patient developed blast crisis while on TKI treatment 8 months after initial diagnosis. With a median follow-up time of 46.1 months, 20 of 22 patients who received TKI therapy and had detailed follow-up information achieved complete cytogenetic remission or deeper, 15 achieved major molecular remission or deeper, and 10 achieved molecularly undetectable leukemia. In conclusion, given the frequent occurrence of prior or concurrent malignancies, aleukemic presentation, and low level of t(9;22)(q34;q11.2)/BCR::ABL1, misdiagnosis or delayed diagnosis is common among these patients. While these patients generally respond well to TKIs, rare patients may develop blastic transformation. It is therefore important for pathologists and hematologists to be aware of this highly unusual presentation of CML to ensure timely diagnosis and appropriate management.
The kynurenine pathway (KP) is the principal metabolic route for the essential amino acid tryptophan (TRP). Recent advances have highlighted a pivotal role for several KP metabolites in inflammatory diseases, including ulcerative colitis (UC). However, the alterations of KP enzymes and their functional impact in UC remain poorly defined. Here, we focused on kynurenine 3-monooxygenase (KMO) and kynureninase (KYNU), which serve as critical branching enzymes in the KP. We observed that dextran sodium sulfate (DSS)-induced colitis mice exhibited disturbed TRP metabolism along with KMO and KYNU upregulated. In patients with active UC, both the expression of KMO and KYNU were positively correlated with inflammatory factors TNF-α and IL-1β. Pharmacological blockade of KMO or genetic silencing of KYNU suppressed IL-1β-triggered proinflammatory cytokines expression in intestinal epithelial cells. Furthermore, blockage of KMO by selective inhibitor Ro 61-8048 alleviated the symptoms of DSS-induced colitis in mice, accompanied by an expanded NAD+ pool and redox balance restoration. The protective role of Ro 61-8048 may be partly due to its effect on KP regulation, particularly in enhancing kynurenic acid production. In summary, our study provides new evidence for the proinflammatory property of KMO and KYNU in intestinal inflammation, hinting at a promising therapeutic approach in UC through targeting these enzymes.
Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 4 or 5. Patient with indications for biopsy unless breast biopsy was performed in the last 3 months (except for FNA). Thermography examination was performed with the use of Braster device.
Doxorubicin was given at 50 mg/m² by IV slow push, followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life. Cycles were repeated every 2 weeks.
The invention relates to universal dead vaccines for specific treatment of and prevention from dermatomycosis in animals and to the respective immunogenic mycotic strains. They are produced in a simplified method, have stable immunogenic properties, complete assortment of exo- and endoantigenes of the dermatophytic cultures and cause no side effects in animals. The following mycotic strains are used as vaccination strains: Trychophyton verrucosum, T. mentagrophytes, T. equinum, Microsporum canis, M. canis var. obesum, M. canis var. distortum, M. gypseum. Vaccines can be produced by the combination of antigen material of the above strains and a suitable carrier. 26 claims
Ten subjects will be administered 10mg PA1010 after overnight fasting for 10 hours in the first cycle, and then will be administered 10mg PA1010 within 30 minutes after high-fat meal in the second cycle. They will receive a single dose in each cycle and will be observed for four days. The cleaning period between the two cycles is 10 days.
A flavour delivery system is disclosed which offers the combination of improved flavour intensity and extension and, when incorporated into chewing gums, provides desired softness to the gum to facilitate the reduction in softening additives that conventionally add moisture thereto. The present delivery system comprises a composite of a flavour and a resin in a homogeneous mixture with each other, the flavour being present in an amount of from 20% to 80% of the final delivery system, with the resin being present as from 80% to 20% of the system. Optionally, an emulsifier may be added to an amount of up to 25% by weight. In a further embodiment, the delivery system of the present invention may include up to 25% by weight of a sweetener such as acesulfame-K. The present delivery system finds use in comestibles such as chewing gum compositions and other food products, pharmaceuticals, and scratch-and-sniff and aroma packaging products. The delivery system may be incorporated as a liquid or may be prepared in particulate form.
This invention is directed to compounds of the formula and the pharmaceulically-acceptable salts thereof, where the subslituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this Invention are useful for (the treatment and prevention of osleoporosis. congestive heart failure, frailly associated with aging, obesity; accelerating bone fracture repair, attenuating .protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeoslasis or renal homeostasis. The compounds of (he present invention are also useful in treating osleoporosis when used in combination with: a bisphosphonale compound such as alendronale; estrogen. premarin, and optionally progesterone; an estrogen agonist or antagonist; or cslcilonin, and pharmaceutical compositions useful therefor. Further, (he presenl invention is directed (o pharmaceutical compositions useful for increasing (he endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growlh hormone secretagogue selected from GHRP-6. Hexarelin. GHRP-1. growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920. The invention is also directed lo intermediates useful in the preparation of compounds of formula I.
General: Patients with impaired gag reflex, unconscious, or semiconscious patients, and patients prone to regurgitation or aspiration should be observed during the administration of PEG-3350 and Electrolytes for Oral Solution, especially if it is administered via nasogastric tube. If a patient experiences severe bloating, distention or abdominal pain, administration should be slowed or temporarily discontinued until the symptoms abate. If gastrointestinal obstruction or perforation is suspected, appropriate studies should be performed to rule out these conditions before administration of PEG-3350 and Electrolytes for Oral Solution. 

Information for patients: PEG-3350 and Electrolytes for Oral Solution produces a watery stool which cleanses the bowel before examination. Prepare the solution according to the instructions on the bottle. It is more palatable if chilled. For best results, no solid food should be consumed during the 3 to 4 hour period before drinking the solution, but in no case should solid foods be eaten within 2 hours of taking PEG-3350 and Electrolytes for Oral Solution. 

Drink 240 mL (8 oz.) every 10 minutes. Rapid drinking of each portion is better than drinking small amounts continuously. The first bowel movement should occur approximately one hour after the start of PEG-3350 and Electrolytes for Oral Solution administration. You may experience some abdominal bloating and distention before the bowels start to move. If severe discomfort or distention occur, stop drinking temporarily or drink each portion at longer intervals until these symptoms disappear. Continue drinking until the watery stool is clear and free of solid matter. This usually requires at least 3 liters and it is best to drink all of the solution. Any unused portion should be discarded. 

Drug Interactions: Oral medication administered within one hour of the start of administration of PEG-3350 and Electrolytes for Oral Solution may be flushed from the gastrointestinal tract and not absorbed. 

Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenic and reproductive studies with animals have not been performed. 

Pregnancy: Category C. Animal reproduction studies have not been conducted with PEG-3350 and Electrolytes for Oral Solution. It is also not known whether PEG-3350 and Electrolytes for Oral Solution can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. PEG-3350 and Electrolytes for Oral Solution should be given to a pregnant woman only if clearly needed. Pediatric Use: Safety and effectiveness in children have not been established.
An apparatus, system and method for exercise tracking that comprises at least one mother unit, equipment tag, base unit, and RF user tag. The mother unit comprises equipment tag reader and sensor and is joined to an equipment in a gym. The tag is placed on the equipment and in communication with the mother unit. The base unit comprises a RFID reader. A plurality of mother units is in communication with the base unit. The RF and GPS enabled user tag is provided and joined to user in gym and in communication with the mother unit. The apparatus is a substantially hands-free. User profile and user exercise data is captured. A computer system in communication with the base unit is provided. Data captured by the mother unit is communicated to and analyzed by the computer system, and feedback communicated to the mother unit is communicated to user.